Overview
- Editors:
-
-
Jacqueline Saw
-
Vancouver General Hospital, University of British Columbia, Vancouver, Canada
-
Saibal Kar
-
Cardiovascular Intervention Center Research, Cedars-Sinai Medical Center, Los Angeles, USA
-
Matthew J. Price
-
Scripps Translational Science Institute, Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, USA
- Unique and timely examination of left atrial appendage closure technique and devices
- Explores the use of left atrial appendage closure in the reduction of thromboembolism in patients with atrial fibrillation
- Discusses current percutaneous approaches and devices available for left atrial appendage closure
Access this book
Other ways to access
Table of contents (20 chapters)
-
-
Rationale for LAA Closure
-
-
-
-
-
- Creighton W. Don, Andrew C. Cook, Mark Reisman
Pages 45-57
-
Surgical Approaches for LAA Closure
-
-
- Hasib Hanif, Richard Whitlock
Pages 61-80
-
Imaging for LAA Closure
-
-
-
- Sergio Berti, Umberto Paradossi, Gennaro Santoro
Pages 101-115
-
- Jacqueline Saw, Joao Pedro Lopes, Mark Reisman, Hiram G. Bezerra
Pages 117-132
-
Percutaneous LAA Closure Devices and Trial Results
-
Front Matter
Pages 133-133
-
-
- Karen P. Phillips, Saibal Kar
Pages 143-168
-
- Jacqueline Saw, Saibal Kar, Matthew J. Price
Pages 169-180
-
-
- Xavier Freixa, Apostolos Tzikas, Réda Ibrahim
Pages 195-203
-
- Arun Kanmanthareddy, Sampath Gunda, Nitish Badhwar, Randall J. Lee, Dhanunjaya Lakkireddy
Pages 205-223
-
About this book
Percutaneous left atrial appendage (LAA) closure is an emerging technology for thromboembolic prevention in patients with atrial fibrillation (AF). The first human implantation of an LAA device occurred in 2001, and since then four devices have received CE mark approval. These devices are being widely used in Europe for LAA closure in patients who are poor candidates for long-term oral anticoagulation. In the US, the WATCHMAN device (Boston Scientific) is anticipated to receive FDA approval imminently for AF patients who are warfarin-eligible. This approval is projected to significantly expand the indications for LAA closures worldwide. Thus, the volume of procedures is anticipated to escalate. This book discusses the epidemiology of AF as a cause of stroke; the use of LAA closure in the reduction of thromboembolism with AF; early surgical approaches and novel surgical devices for LAA closure; and current percutaneous approaches and devices available for LAA closure. The emphasis of this book is on percutaneous technical approaches and contemporary trial results on the leading devices (PLAATO, WATCHMAN, Amplatzer Cardiac Plug, and LARIAT). It also reviews unapproved devices in development, in both clinical and pre-clinical phases.
Editors and Affiliations
-
Vancouver General Hospital, University of British Columbia, Vancouver, Canada
Jacqueline Saw
-
Cardiovascular Intervention Center Research, Cedars-Sinai Medical Center, Los Angeles, USA
Saibal Kar
-
Scripps Translational Science Institute, Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, USA
Matthew J. Price
About the editors
Jacqueline Saw, MD, FRCPC, FACC, FSCAI Clinical Associate Professor University of British Columbia Head, VGH Cardiology Clinical Trials Research Program Director, VGH Interventional Cardiology Fellowship Vancouver General Hospital 2775 Laurel Street, Level 9 Vancouver, V5Z1M9, British Columbia Canada Saibal Kar, MD, FACC Director, Interventional Cardiology Research Cedars-Sinai Medical Center 8631 W. 3rd Street, #415E Los Angeles, CA 90048 Matthew J. Price, MD, FACC, FSCAI Director, Cardiac Catheterization Laboratory Division of Cardiovascular Diseases Scripps Clinic Assistant Professor Scripps Translational Science Institute 10666 North Torrey Pines Road, Maildrop S1056 La Jolla, CA 92037 Jacqueline Saw is the editor of Carotid Artery Stenting: The Basics (978-1-60327-313-8, 2009) and Handbook of Complex Percutaneous Carotid Intervention (978-1-58829-605-4, 2007), both of which are volumes in the Contemporary Cardiology series.
